Name:
REDUCE-IT Subanalysis Targets US Population
Description:
REDUCE-IT Subanalysis Targets US Population
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/fc5f59ae-f6b6-4e04-888f-62878167faeb/thumbnails/fc5f59ae-f6b6-4e04-888f-62878167faeb.jpeg?sv=2019-02-02&sr=c&sig=qMUP6HQUyI7RCMmJdj0ia7ev52sydsaCBKPEmbrcTvI%3D&st=2024-12-21T14%3A37%3A29Z&se=2024-12-21T18%3A42%3A29Z&sp=r
Duration:
T00H03M48S
Embed URL:
https://stream.cadmore.media/player/fc5f59ae-f6b6-4e04-888f-62878167faeb
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/fc5f59ae-f6b6-4e04-888f-62878167faeb/18519192.mp3?sv=2019-02-02&sr=c&sig=L3IZKISZEDY7bnzj5KBjzPI0JK%2BMhbFAYg2qhj7CZn0%3D&st=2024-12-21T14%3A37%3A29Z&se=2024-12-21T16%3A42%3A29Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's, The Heart Board Review, and other online resources available only through AccessCardiology.com. >> [Background Music] I wanted to revisit the REDUCE-IT trial. As you remember, REDUCE-IT trial is an international trial published earlier in 2019. Dr. Bernie here and welcome to Practice Impact Extra. At the November 2019 American Heart Meetings, a further trial analysis was added, and included the sub-analysis of the specific USA population enrolled and also of course effective analysis.
To summarize and to revisit the primary goal of REDUCE-IT, it was to assess the safety and benefit of pure EPA icosapent ethyl compared to placebo in reducing CV events among patients with high triglycerides, with controlled LDL levels, on statin treatment. Eight thousand patients were randomized to icosapent 2 grams twice a day or matching placebo for a follow period of 4.9 years.
Randomization was stratified by primary and secondary prevention. Primary CV outcome including CV death, MI, stroke, coronary artery revascularization demonstrated icosapent was superior to placebo in patients with known CV disease, secondary prevention, and also those at high risk with diabetes. Other studies suggested outcomes could be different for the US population and, therefore, a sub-analysis was undertaken.
The primary outcome in the United States population again showed superiority of the icosapent in reducing MACE and all-cause mortality. What about cost effectiveness analysis? Well, this demonstrated an overall cost dominant saving compared to placebo. I was somewhat interested in just how pure EPA was able to demonstrate the results that we saw in REDUCE-IT and what possible mechanism is there for this to action and the results.
The EVAPORATE trial was presented also at the American Heart Meetings in November 2019 and this was a clinically relevant trial that was designed to assess the efficacy of a icosapent compared to placebo in reducing plaque burden in patients with documented coronary artery disease already on a statin. The interim results were reported at the nine-month interval and indicated icosapent 4 grams per day reduced the total plaque volume documented on CTA.
These results may explain the CV benefits that we note in the REDUCE-IT trial. So what's the take-home message here? I believe this trial, the REDUCE-IT trial, is actionable, in practice impacting right now for individuals with high triglycerides, with established CV disease or those at high risk with diabetes. Thanks for joining me and see you next time on Practice Impact Extra.
>> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to Access Cardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features. To subscribe or learn more, please visit AccessCardiology.com.
